On April 17, the U.S Food and Drug Administration (FDA) approved omidubicel-onlv for use in adult and pediatric patients (12 years of age and older) with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
For more information read the FDA announcement.
Posted 4/19/2023
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
